yields | Benzinga benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
For investors, ARKG’s active management and utility are vital because the fund is flexible and able to capitalize on genomics advancements more rapidly than index-based rivals. Those advancements include gene editing.
“Crispr-Cas9 is the second generation of technologies that seek to repair thousands of inherited genetic disorders and battle cancer in new ways. Gene editing is advancing so quickly that next-generation technologies are already on the heels of Crispr-Cas9, including a more-precise tool called base editing,” reports Bill Alpert for
Barron’s.
The CRISPR technology may also be under the spotlight as another disease fighting tool, with the world refocusing on the need for improved healthcare solutions.
Investors have had a rough time betting on aducanumab
Biogen’s experimental treatment for Alzeheimer’s disease. The company called its clinical trials a failure, then a success. Government reviewers favored approval, then a panel of outside experts found Biogen’s studies inconclusive.
The stock (ticker: BIIB) has yo-yoed between 268 and 375 in the last year, with it trading around $279 by mid-Thursday. That was up 5% from the open, and one of the things lifting it might have been a hopeful note from Robyn Karnauskas, at Truist Securities.
In her Thursday note, Karnauskas said that discussions about aducanumab’s approval seem to be quite alive between Biogen and the U.S. Food and Drug Administration. She reaches that conclusion, based on comments this week at an Alzheimer’s conference by Samantha Haeberlein, the head of Alzheimer’s drug development at Biogen.